DOCSLIB.ORG

Percept Is Different

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

percept ® is different... Australia’s most advanced and comprehensive non-invasive prenatal test perce ® cell-free DNA pt prenatal test Why percept® percept is Australia’s most comprehensive non-invasive prenatal testing (NIPT) service. Advanced bioinformatics means percept is the only NATA/RCPA accredited Australian NIPT service to assess all 24 chromosomes, (chromosomes 1-22 and the X & Y chromosomes). This means we can identify additional genetic conditions like: • rare autosomal trisomies; • large segmental genetic imbalances like deletions and duplications. These are reported as additional findings; • familial balanced translocation analysis; • all our tests are full supported by clinical interpretation and genetic counselling at no additional cost. 1. percept ® in numbers percept includes our integrated genetic counselling Clinical utility of percept Condition Test Frequency service, so patients and 1 in 74 Conventional NIPT (21,18, 13) (based on VCGS referral data) health professionals are fully percept advanced NIPT Trisomy 21 1 in 113 Trisomy 18 1 in 420 informed and supported Trisomy 13 1 in 436 Additional analysis by percept Rare trisomies (other than 21, 18, 13) 1 in 285 (PPV 50-65%)1,2 Additional findings(dels & dups) 1 in 612 (PPV 53%) Additional high risk cases called by percept 1 in 200 (PPV 50-65%) Additional clinically relevant cases 1 in 300-400 detected by percept Compared to micro-deletion syndrome panels offered by other providers Micro-deletion syndrome panels Approx 1 in 2,100 (PPV 0-18%) 3-8 Therefore... • Our analysis pipeline detects clinically significant genetic changes that occur more frequently and with a higher positive predictive value (PPV) than micro-deletion syndromes offered through other providers. • Using a genome wide approach means genetic changes can be detected across all chromosomes and is not limited to a small number of targeted regions. • The size of the genetic change detectable is dependent on a number of quality measures which includes fetal fraction and genomic location, but on average is approximately 10 mega bases in size. 2. Explained: rare autosomal trisomies & additional findings Rare autosomal trisomies Additional findings • involve all chromosomes other than 21, 18, 13 & the • advanced bioinformatics means the entire length of every sex chromosomes; autosome is analysed, representing an analysis similar to • individually occur less frequently than 21, 18 & 13 but a traditional karyotype; collectively are as frequent as trisomy 13 or 18; • large deletions & duplications can be associated with • up to 76% of rare trisomies detected by percept are serious congenital malformations & intellectual disability; clinically relevant to the pregnancy; • test sensitivity & genomic size of detectable imbalances • rare trisomies may be associated with miscarriages, is dependent on several factors, including fetal fraction; intra-uterine growth retardation, premature labour, • important to note that a low risk NIPT result does not compromised placental function, and as live birth exclude the presence of all deletions & duplications. with serious congenital anomalies. Examples of additional findings from percept® Case report - Pallister-Killian syndrome Chromosome imbalance Condition Chromosome 2 - partial monosomy 2q 2q37 deletion syndrome A. Chromosome 3 - partial monosomy 3p 3p deletion syndrome Chromosome 4 - partial monosomy 4p Wolf-Hirschhorn syndrome Chromosome 5 - partial monosomy 5p Cri-du-chat syndrome Chromosome 9 - tetrasomy 9p Tetrasomy 9p syndrome B. A: WISECONDOR plot showing Chromosome 10 - partial monosomy 10p 16 Mb deletion increased sequence counts for the Chromosome 11 - partial monosomy 11q Jacobsen syndrome p-arm of chromosome 12 (shown Chromosome 12 - tetrasomy 12p Pallister-Killian syndrome by red line & purple block). Chromosome 15 - partial trisomy 15q 27Mb duplication Chromosome 17 - partial monosomy 17p Miller-Dieker lissencephaly syndrome B: Conventional karyotyping on Chromosome 18 - tetrasomy 18p Tetrasomy 18p syndrome amniocytes confirmed this to Chromosome 22 - partial trisomy 22q 11 Mb duplication be mosaicism for tetrasomy of Chromosome 22 - der(22)t(11;22) Emanuel syndrome chromosome 12p. Uniparental disomy post trisomy 15 NIPT Prader-Willi syndrome All confirmed by CVS or amniocentesis ® Test Features for Routine Analysis percept other providers Why percept is different... Analysis of all 24 chromosomes ✘ Screening for rare autosomal trisomies ✘# Additional findings (large segmental deletions/duplications) ✘ VCGS is a not-for-profit Discrimination of mosaicism (maternal & placental) * ✘ Translocation analysis for known carriers ** ✘ specialist genetics service; Co-twin demise ** ✘ Triplet pregnancies ** ✘ all proceeds support VCGS Key Service Features Rapid turn around time 3-5 days 4-10 days medical research Fully integrated laboratory and clinical service variable Lower limit of detection for trisomy 2.5% fetal fraction up to 4% fetal fraction Low test failure rate 0.2% up to 1-3% Full genetic data interrogation & interpretation variable Clinical support provided with all testing variable Conditions detected (n=30,000) Sensitivity PPV Trisomy 21 >99% 99% Trisomy 18 >98% >95% Trisomy 13 >99% >85% Monosomy X >95% >30%*** Other sex chromosome anomalies (XXX, XXY, XYY) LD 75-92% Fetal sex >99% >99% Rare trisomies (n=16,885)1 LD (for each) 50-65%1,2,° Additional findings (dels & dups >10Mb) (n=15,600)^ 78% 53% Known translocations (12 high risk cases/75 tests) 100% 100% # Offered by one other provider * This is not always definitive but can be used to help direct care of the pregnancy ** Prior notification required as additional clinical information is needed and sample collection may vary *** True fetal 45,X (including variants). Most causes of false positive results are confined placental mosaicism & maternal contributions (VCGS data on file) LD = limited data ° This value represents findings confirmed in the fetus & those confined to the placenta but considered clinically relevant1,2 ^ VCGS NATA validation study (2017) (VCGS data on file) 4. References 1. Pertile MD, Halks-Miller M, Flowers N, Barbacioru C, Kinnings SL, Vavrek D, et al. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease. Sci Transl Med. 2017;9(405). 2. Pertile MD. Chapter 7 - Genome-Wide Cell-Free DNA-Based Prenatal Testing for Rare Autosomal Trisomies and Subchromosomal Abnormalities. In: Page-Christiaens L, Klein H-G, editors. Noninvasive Prenatal Testing (NIPT): Academic Press; 2018. p. 97-123. 3. Hui L. Cell-free DNA testing for 22q11.2 deletion syndrome: appraising the viability, effectiveness and appropriateness of screening. Ultrasound Obstet Gynecol. 2016;47(2):137-41. 4. Yaron Y, Jani J, Schmid M, Oepkes D. Current Status of Testing for Microdeletion Syndromes and Rare Autosomal Trisomies Using Cell-Free DNA Technology. Obstet Gynecol. 2015;126(5):1095-9. ® 5. Valderramos SG, Rao RR, Scibetta EW, Silverman NS, Han CS, Platt LD. Cell-free DNA screening in clinical practice: abnormal perce autosomal aneuploidy and microdeletion results. Am J Obstet Gynecol. 2016;215(5):626 e1- e10. cell-free DNA pt prenatal test 6. Gross SJ, Stosic M, McDonald-McGinn DM, Bassett AS, Norvez A, Dhamankar R, et al. Clinical experience with single- nucleotide polymorphism-based non-invasive prenatal screening for 22q11.2 deletion syndrome. Ultrasound Obstet Gynecol. 2016;47(2):177-83. P) 1300 11 8247 E) [email protected] 7. Martin K, Iyengar S, Kalyan A, Lan C, Simon AL, Stosic M, et al. Clinical experience with a single-nucleotide polymorphism- based non-invasive prenatal test for five clinically significant microdeletions. Clin Genet. 2018;93(2):293-300. 8. National Library of Medicine (US). Genetics Home Reference [Internet]. Bethesda (MD). Available from: https://ghr.nlm.nih.gov/ 5..
Recommended publications
  • Monosomy X Turner Syndrome Information for Patients

    Monosomy X Turner Syndrome Information for Patients

    Monosomy X Turner syndrome Information for patients The healthcare professional responsible for your care has given you this leaflet because you have been identified by the Harmony® Prenatal Test as having a high probability of a chromosome disorder in your pregnancy. This fact sheet contains more information about the particular genetic disorder mentioned in your Harmony report. We recommend that you also discuss your result with an experienced doctor or genetic counsellor. Turner syndrome, or Monosomy X, is a sex chromosome disorder that occurs in females when there is only one copy of the X chromosome instead of the expected two (Figure 1). It occurs in at least one in every 2,500 female births. Monosomy X may be associated with an increased risk of miscarriage in the first or second trimester. More than half of those withT urner syndrome will be mosaic, meaning some of their cells have just one X chromosome and the other cells have two X chromosomes. Features and symptoms of Turner syndrome include subtle changes in physical appearance, short stature, infertility and learning difficulties, as well as some potential health conditions, including cardiac conditions, hypothyroidism, diabetes and autoimmune disease. Babies who are born with Turner syndrome could have a number of the features and symptoms of the syndrome, however, not everyone will have them all and severity will vary significantly. Mosaicism also plays a role in the varied severity of the syndrome. Although there is no cure for Turner syndrome, many of the associated symptoms can be treated. Girls with Turner syndrome may need regular health checks of their heart, kidneys and reproductive system throughout their lives.
  • The National Economic Burden of Rare Disease Study February 2021

    The National Economic Burden of Rare Disease Study February 2021

    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
  • Chromosome 18

    Chromosome 18

    Chromosome 18 Description Humans normally have 46 chromosomes in each cell, divided into 23 pairs. Two copies of chromosome 18, one copy inherited from each parent, form one of the pairs. Chromosome 18 spans about 78 million DNA building blocks (base pairs) and represents approximately 2.5 percent of the total DNA in cells. Identifying genes on each chromosome is an active area of genetic research. Because researchers use different approaches to predict the number of genes on each chromosome, the estimated number of genes varies. Chromosome 18 likely contains 200 to 300 genes that provide instructions for making proteins. These proteins perform a variety of different roles in the body. Health Conditions Related to Chromosomal Changes The following chromosomal conditions are associated with changes in the structure or number of copies of chromosome 18. Distal 18q deletion syndrome Distal 18q deletion syndrome occurs when a piece of the long (q) arm of chromosome 18 is missing. The term "distal" means that the missing piece (deletion) occurs near one end of the chromosome arm. The signs and symptoms of distal 18q deletion syndrome include delayed development and learning disabilities, short stature, weak muscle tone ( hypotonia), foot abnormalities, and a wide variety of other features. The deletion that causes distal 18q deletion syndrome can occur anywhere between a region called 18q21 and the end of the chromosome. The size of the deletion varies among affected individuals. The signs and symptoms of distal 18q deletion syndrome are thought to be related to the loss of multiple genes from this part of the long arm of chromosome 18.
  • First Case Report of Maternal Mosaic Tetrasomy 9P Incidentally Detected on Non-Invasive Prenatal Testing

    First Case Report of Maternal Mosaic Tetrasomy 9P Incidentally Detected on Non-Invasive Prenatal Testing

    G C A T T A C G G C A T genes Article First Case Report of Maternal Mosaic Tetrasomy 9p Incidentally Detected on Non-Invasive Prenatal Testing Wendy Shu 1,*, Shirley S. W. Cheng 2 , Shuwen Xue 3, Lin Wai Chan 1, Sung Inda Soong 4, Anita Sik Yau Kan 5 , Sunny Wai Hung Cheung 6 and Kwong Wai Choy 3,* 1 Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 2 Clinical Genetic Service, Hong Hong Children Hospital, Ngau Tau Kok, Hong Kong, China; [email protected] 3 Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong, China; [email protected] 4 Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 5 Prenatal Diagnostic Laboratory, Tsan Yuk Hospital, Sai Ying Pun, Hong Kong, China; [email protected] 6 NIPT Department, NGS Lab, Xcelom Limited, Hong Kong, China; [email protected] * Correspondence: [email protected] (W.S.); [email protected] (K.W.C.); Tel.: +852-25-957-359 (W.S.); +852-35-053-099 (K.W.C.) Abstract: Tetrasomy 9p (ORPHA:3390) is a rare syndrome, hallmarked by growth retardation; psychomotor delay; mild to moderate intellectual disability; and a spectrum of skeletal, cardiac, renal and urogenital defects. Here we present a Chinese female with good past health who conceived her pregnancy naturally. Non-invasive prenatal testing (NIPT) showed multiple chromosomal aberrations were consistently detected in two sampling times, which included elevation in DNA from Citation: Shu, W.; Cheng, S.S.W.; chromosome 9p.
  • Sema4 Noninvasive Prenatal Select

    Sema4 Noninvasive Prenatal Select

    Sema4 Noninvasive Prenatal Select Noninvasive prenatal testing with targeted genome counting 2 Autosomal trisomies 5 Trisomy 21 (Down syndrome) 6 Trisomy 18 (Edwards syndrome) 7 Trisomy 13 (Patau syndrome) 8 Trisomy 16 9 Trisomy 22 9 Trisomy 15 10 Sex chromosome aneuploidies 12 Monosomy X (Turner syndrome) 13 XXX (Trisomy X) 14 XXY (Klinefelter syndrome) 14 XYY 15 Microdeletions 17 22q11.2 deletion 18 1p36 deletion 20 4p16 deletion (Wolf-Hirschhorn syndrome) 20 5p15 deletion (Cri-du-chat syndrome) 22 15q11.2-q13 deletion (Angelman syndrome) 22 15q11.2-q13 deletion (Prader-Willi syndrome) 24 11q23 deletion (Jacobsen Syndrome) 25 8q24 deletion (Langer-Giedion syndrome) 26 Turnaround time 27 Specimen and shipping requirements 27 2 Noninvasive prenatal testing with targeted genome counting Sema4’s Noninvasive Prenatal Testing (NIPT)- Targeted Genome Counting analyzes genetic information of cell-free DNA (cfDNA) through a simple maternal blood draw to determine the risk for common aneuploidies, sex chromosomal abnormalities, and microdeletions, in addition to fetal gender, as early as nine weeks gestation. The test uses paired-end next-generation sequencing technology to provide higher depth across targeted regions. It also uses a laboratory-specific statistical model to help reduce false positive and false negative rates. The test can be offered to all women with singleton, twins and triplet pregnancies, including egg donor. The conditions offered are shown in below tables. For multiple gestation pregnancies, screening of three conditions
  • RD-Action Matchmaker – Summary of Disease Expertise Recorded Under

    RD-Action Matchmaker – Summary of Disease Expertise Recorded Under

    Summary of disease expertise recorded via RD-ACTION Matchmaker under each Thematic Grouping and EURORDIS Members’ Thematic Grouping Thematic Reported expertise of those completing the EURORDIS Member perspectives on Grouping matchmaker under each heading Grouping RD Thematically Rare Bone Achondroplasia/Hypochondroplasia Achondroplasia Amelia skeletal dysplasia’s including Achondroplasia/Growth hormone cleidocranial dysostosis, arthrogryposis deficiency/MPS/Turner Brachydactyly chondrodysplasia punctate Fibrous dysplasia of bone Collagenopathy and oncologic disease such as Fibrodysplasia ossificans progressive Li-Fraumeni syndrome Osteogenesis imperfecta Congenital hand and fore-foot conditions Sterno Costo Clavicular Hyperostosis Disorders of Sex Development Duchenne Muscular Dystrophy Ehlers –Danlos syndrome Fibrodysplasia Ossificans Progressiva Growth disorders Hypoparathyroidism Hypophosphatemic rickets & Nutritional Rickets Hypophosphatasia Jeune’s syndrome Limb reduction defects Madelung disease Metabolic Osteoporosis Multiple Hereditary Exostoses Osteogenesis imperfecta Osteoporosis Paediatric Osteoporosis Paget’s disease Phocomelia Pseudohypoparathyroidism Radial dysplasia Skeletal dysplasia Thanatophoric dwarfism Ulna dysplasia Rare Cancer and Adrenocortical tumours Acute monoblastic leukaemia Tumours Carcinoid tumours Brain tumour Craniopharyngioma Colon cancer, familial nonpolyposis Embryonal tumours of CNS Craniopharyngioma Ependymoma Desmoid disease Epithelial thymic tumours in
  • Mosaic Tetrasomy 9P at Amniocentesis: Prenatal Diagnosis, Molecular Cytogenetic Characterization, and Literature Review

    Mosaic Tetrasomy 9P at Amniocentesis: Prenatal Diagnosis, Molecular Cytogenetic Characterization, and Literature Review

    Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 79e85 Contents lists available at ScienceDirect Taiwanese Journal of Obstetrics & Gynecology journal homepage: www.tjog-online.com Short Communication Mosaic tetrasomy 9p at amniocentesis: Prenatal diagnosis, molecular cytogenetic characterization, and literature review Chih-Ping Chen a,b,c,d,e,f,*, Liang-Kai Wang a, Schu-Rern Chern b, Peih-Shan Wu g, Yu-Ting Chen b, Yu-Ling Kuo h, Wen-Lin Chen a, Meng-Shan Lee a, Wayseen Wang b,i a Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan b Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan c Department of Biotechnology, Asia University, Taichung, Taiwan d School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan e Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan f Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan g Gene Biodesign Co. Ltd, Taipei, Taiwan h Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan i Department of Bioengineering, Tatung University, Taipei, Taiwan article info abstract Article history: Objective: This study was aimed at prenatal diagnosis of mosaic tetrasomy 9p and reviewing the Accepted 17 December 2013 literature. Materials and methods: A 37-year-old woman underwent amniocentesis at 20 weeks’ gestation because Keywords: of advanced maternal age and fetal ascites. Cytogenetic analysis of cultured amniocytes revealed 21.4% amniocentesis (6/28 colonies) mosaicism for a supernumerary i(9p). Repeat amniocentesis was performed at 23 weeks’ mosaicism gestation. Array comparative genomic hybridization, interphase fluorescence in situ hybridization, and supernumerary isochromosome 9p quantitative fluorescent polymerase chain reaction were applied to uncultured amniocytes, and con- tetrasomy 9p ventional cytogenetic analysis was applied to cultured amniocytes.
  • Aneuploidy and Aneusomy of Chromosome 7 Detected by Fluorescence in Situ Hybridization Are Markers of Poor Prognosis in Prostate Cancer'

    Aneuploidy and Aneusomy of Chromosome 7 Detected by Fluorescence in Situ Hybridization Are Markers of Poor Prognosis in Prostate Cancer'

    [CANCERRESEARCH54,3998-4002,August1, 19941 Advances in Brief Aneuploidy and Aneusomy of Chromosome 7 Detected by Fluorescence in Situ Hybridization Are Markers of Poor Prognosis in Prostate Cancer' Antonio Alcaraz, Satoru Takahashi, James A. Brown, John F. Herath, Erik J- Bergstralh, Jeffrey J. Larson-Keller, Michael M Lieber, and Robert B. Jenkins2 Depart,nent of Urology [A. A., S. T., J. A. B., M. M. U, Laboratory Medicine and Pathology (J. F. H., R. B. fl, and Section of Biostatistics (E. J. B., J. J. L-JCJ, Mayo Clinic and Foundation@ Rochester, Minnesota 55905 Abstract studies on prostate carcinoma samples. Interphase cytogenetic analy sis using FISH to enumerate chromosomes has the potential to over Fluorescence in situ hybridization is a new methodologj@which can be come many of the difficulties associated with traditional cytogenetic used to detect cytogenetic anomalies within interphase tumor cells. We studies. Previous studies from this institution have demonstrated that used this technique to identify nonrandom numeric chromosomal alter ations in tumor specimens from the poorest prognosis patients with path FISH analysis with chromosome enumeration probes is more sensitive ological stages T2N@M,Jand T3NOMOprostate carcinomas. Among 1368 than FCM for detecting aneuploid prostate cancers (4, 5, 7). patients treated by radical prostatectomy, 25 study patients were ascer We designed a case-control study to test the hypothesis that spe tamed who died most quickly from progressive prostate carcinoma within cific, nonrandom cytogenetic changes are present in tumors removed 3 years of diagnosis and surgery. Tumors from 25 control patients who from patients with prostate carcinomas with poorest prognoses .
  • CYTOGENETICS: Rotation Director: Robert Zori, M

    CYTOGENETICS: Rotation Director: Robert Zori, M

    CYTOGENETICS: Rotation director: Roberto Zori, M.D. 1. Description of the rotations: Training in cytogenetics involves training in I) prenatal and medical cytogenetics, II) cancer cytogenetics, and III) pediatric pathology. The dedicated 4-week cytogenetics rotation involves 3 weeks art the R. C. Philips Cytogenetics Laboratory and 1 wee of seminars held on the UF Health Science Center campus. At the R.C. Philips Cytogenetics Laboratory at Tacachale State Home (Gainesville, FL) residents are oriented to the basic laboratory methods used to construct and interpret karyotypes. This laboratory focuses on prenatal karyotypes and medical karyotypes for syndromic diagnosis (e.g., Down Syndrome) as well as cancer diagnosis (Competency #2: Medical Knowledge). Molecular techniques are employed such as florescent in situ hybridization (FISH). The residents learn to interpret the resulting karyotype and construct consultative reports. Residents will then be able to correlate this data with the clinical history and physical examination through a review of the patient's on-line medical record (OLMR), chart or by contacting the clinical service. Seminar topics include: Introduction to genetics, modes of inheritance, techniques, syndromes, and cytogenetics (Competency #2: Medical Knowledge). The objective of these seminars is to discuss nomenclature and classic genetic syndromes involving chromosomal disorders. At the conclusion of the rotation, each resident will be expected to present a seminar to the pathology faculty and residents on a topic that the resident found interesting in cytogenetics (Competencies #3: Practice-Based Learning and Improvement, #4: Communication, and #5 Professionalism). These experiences are supplemented by 1) directed readings, and 2) periodic lectures on the topic cytogenetics.
  • General Contribution

    General Contribution

    24 Abstracts of 37th Annual Meeting A1 A SCREENING METHOD FOR FRAGILE X MUTATION: DETECTION OF THE CGG REPEAT IN FMR-1 GENE BY PCR WITH BIOTIN-LABELED PRIMER. ..Eiji NANBA, Kousaku OHNO and Kenzo TAKESHITA Division of Child Neurology, Institute of Neurological Sciences, Tot- tori University School of Medicine. Yonago We have developed a new polymerase chain reaction(PCR)-based method for detection of the CGG repeat in FMR-1 gene. No specific product from PCR was detected on the gel with ethidium bromide staining, because 7-deaza-2'-dGTP is necessary for amplification of this repeat. Biotin-labeled primer was used for PCR and the product was transferred to a nylon membrane followed the detection of biotin by Smilight kit. The size of PCR product from normal control were slightly various and around 300bp. No PCR product was detected from 3 fragile X male patients in 2 families diagnosed by cytogenetic examination. This method is useful for genetic screen- ing of male mental retardation patients to exclude the fragile X mutation. A2 DNA ANALYSISFOR FRAGILE X SYNDROME Osamu KOSUDA,Utak00GASA, ~.ideynki INH, a~ji K/NAGIJCltI, and Kazumasa ]tIKIJI (SILL Inc., Tokyo) Fragile X syndrome is X-linked disease having the amplification of (CG6)n repeat sequence in the chromsomeXq27.3. We performed Southern blot analysis using three probes recognized repetitive sequence resion. Normal controle showed 5.2Kb with Eco RI digest and 2.7Kb with Eco RI/Bss ttII digest as the germ tines by the Southern blot analysis. However, three cell lines established fro~ unrelated the patients with fragile X showed the abnormal bands between 5.2 and 7.7Kb with Eco RI digest, and between 2.7 and 7.7Kb with Eco aI/Bss HII digest.
  • Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients

    Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients

    Vol. 11, 621–631, January 15, 2005 Clinical Cancer Research 621 Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients Na´dia Aparecida Be´rgamo,1 that acquisition of monosomy 17 was a significant (P = Luciana Caricati da Silva Veiga,1 0.0012) factor for patients with a previous family history of Patricia Pintor dos Reis,4 Ineˆs Nobuko Nishimoto,3 cancer. Conclusions: The significant associations found in this Jose´ Magrin,3 Luiz Paulo Kowalski,3 4 2 study emphasize that alterations of distinct regions of the Jeremy A. Squire, and Sı´lvia Regina Rogatto genome may be genetic biomarkers for a poor prognosis. 1Department of Genetics, Institute of Biosciences and 2NeoGene Losses of chromosomes 17 and 22 can be associated with Laboratory, Department of Urology, Faculty of Medicine, Sa˜o Paulo a family history of cancer. State University; 3Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Hospital, Sa˜o Paulo, Brazil and 4Department of Cellular and Molecular Biology, Princess Margaret INTRODUCTION Hospital, Ontario Cancer Institute, University of Toronto, Toronto, Carcinomas of the head and neck represent the sixth most Ontario, Canada frequent cancer worldwide and f90% to 95% are squamous cell carcinomas. Tobacco and alcohol consumption are the ABSTRACT most important nongenetic risk factors associated with the Purpose: Genetic biomarkers of head and neck tumors development of head and neck squamous cell carcinomas could be useful for distinguishing among patients with (HNSCC; ref. 1). Estimated age-standardized rates per similar clinical and histopathologic characteristics but 100,000 for 1990 showed 12.8 men and 3.7 women of oral having differential probabilities of survival.
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.